Literature DB >> 28685599

Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage III non-small-cell lung cancer.

Kylie H Kang1, Jimmy T Efird2, Neelesh Sharma3, Michael Yang3, Afshin Dowlati3, Philip Linden3, Mitchell Machtay4, Tithi Biswas4.   

Abstract

AIM: Studies have shown increased pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios to be predictive of survival in various cancers. Our aim was to evaluate the prognostic role of such inflammatory markers in non-small-cell lung cancer (NSCLC).
METHODS: One hundred and sixty-three patients with stage III NSCLC who received definitive treatment were included. Survival analysis was performed using Kaplan-Meier method. Hazard ratios for overall and recurrence-free survival were estimated using Cox proportional hazards model.
RESULTS: Both neutrophil-to-lymphocyte >Q75 (4.5) and lymphocyte nadir values <Q25 (0.25) and their unified values were associated with 90% increased overall mortality risk (p = 0.040) and a nonsignificant 50% decreased recurrence-free survival risk.
CONCLUSION: Our exploratory analysis showed markers of systemic inflammation predicted survival outcomes in advanced NSCLC. Future prospective data analyses are needed to confirm this potential.

Entities:  

Keywords:  NSCLC; inflammatory serum markers; prognostic model

Mesh:

Substances:

Year:  2017        PMID: 28685599     DOI: 10.2217/fon-2017-0045

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  10 in total

1.  Dynamics of neutrophil-to-lymphocyte ratio predict outcomes of metastatic colorectal carcinoma patients treated by FOLFOX.

Authors:  Qian Liu; Yanfeng Xi; Guangzhao He; Xiaoqian Li; Feng Zhan
Journal:  J Gastrointest Oncol       Date:  2021-12

2.  Usefulness of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography combined with the platelet-lymphocyte ratio in predicting the prognosis of nasopharyngeal carcinoma.

Authors:  Wei Jun Xian; Yan Lin Feng; Ying Wang; Ming Yang; Sheng Nan Lu
Journal:  Br J Radiol       Date:  2021-11-23       Impact factor: 3.039

3.  Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio associations with heart and body dose and their effects on patient outcomes in locally advanced non-small cell lung cancer treated with definitive radiotherapy.

Authors:  Wu-Yan Xia; Xue-Ru Zhu; Wen Feng; Jun Liu; Jia-Ming Wang; Chang-Xing Lv; Qin Zhang; Wen Yu; Xu-Wei Cai; Xiao-Long Fu
Journal:  Transl Lung Cancer Res       Date:  2020-10

4.  Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel.

Authors:  Alessandro Russo; Tindara Franchina; Giuseppina R R Ricciardi; Alessandra Battaglia; Antonino Scimone; Rosa Berenato; Antonio Giordano; Vincenzo Adamo
Journal:  J Cell Physiol       Date:  2018-04-19       Impact factor: 6.384

5.  Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: A meta-analysis.

Authors:  Yi Zhang; Bo Chen; Lijuan Wang; Rong Wang; Xianjin Yang
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

6.  Pretreatment neutrophil-to-lymphocyte ratio as an important prognostic marker in stage III locally advanced non-small cell lung cancer: confirmatory results from the PROCLAIM phase III clinical trial.

Authors:  Tithi Biswas; Rohin Gawdi; Charulata Jindal; Sharanya Iyer; Kylie H Kang; David Bajor; Mitchell Machtay; Yuk Ming Choi; Jimmy T Efird
Journal:  J Thorac Dis       Date:  2021-10       Impact factor: 2.895

7.  The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.

Authors:  Yuan Zhang; Yang-Chun Feng; Hong-Ge Zhu; Ting-Chuan Xiong; Yan-Shen Hou; Jia Song; Wei Jiang; Chang-Jun Zhu
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

8.  Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC).

Authors:  Tithi Biswas; Kylie H Kang; Rohin Gawdi; David Bajor; Mitchell Machtay; Charu Jindal; Jimmy T Efird
Journal:  Int J Environ Res Public Health       Date:  2020-10-30       Impact factor: 3.390

9.  A Pilot Study Examining the Prognostic Utility of Tumor Shrinkage on Cone-Beam Computed Tomography (CBCT) for Stage III Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Definitive Chemoradiation.

Authors:  Kylie H Kang; Jimmy T Efird; Tarun K Podder; Yuxia Zhang; Afshin Dowlati; Mitchell Machtay; Charulata Jindal; Tithi Biswas
Journal:  Int J Environ Res Public Health       Date:  2021-03-21       Impact factor: 3.390

10.  Impact of neutrophil-to-lymphocyte ratio throughout the course of chemoradiotherapy on overall survival and distant failure in unresectable stage III non-small cell lung cancer.

Authors:  Hiromitsu Kanzaki; Yasushi Hamamoto; Kei Nagasaki; Toshiyuki Kozuki
Journal:  Jpn J Radiol       Date:  2021-05-17       Impact factor: 2.374

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.